LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis' lead preclinical program is focused on liver regeneration for patients with end stage liver disease. Other therapeutic targets for organ regeneration include the thymus, pancreas, and kidney. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/09/18 | $3,000,000 | Series A |
Juvenescence | undisclosed |
| 10/21/19 | $4,000,000 | Convertible Debt |
Juvenescence Longevity Vision Fund | undisclosed |
| 10/24/23 | $19,000,000 | Series A-2 |
Juvenescence Prime Movers Lab  | undisclosed |
